10-K/A: Premier Amends 10-K, Discloses Governance & Merger

Premier, Inc. amends its annual report, detailing corporate governance, executive compensation, and disclosing a recent merger agreement.

Summary

• Premier, Inc. filed Amendment No. 1 on Form 10-K/A for the fiscal year ended June 30, 2025, to include information required by Part III of Form 10-K, which was omitted from the original filing.
• The amendment includes new certifications from the principal executive officer and principal financial officer pursuant to Section 302 and 906 of the Sarbanes-Oxley Act of 2002.
• The company did not achieve the threshold performance levels for its Fiscal Year 2023 Performance Share Awards (PSAs) for the three-year cycle ending June 30, 2025, resulting in a 0% payout for these awards.
• For Fiscal Year 2025, the Annual Incentive Plan (AIP) payouts for named executive officers (NEOs) were based on a Corporate Score achievement of 113.3% of target.
• The Corporate Score for FY2025 was driven by Non-GAAP Free Cash Flow achieving 150.0% of target, while Consolidated Net Revenue achieved 80.9% and Non-GAAP Consolidated Adjusted EBITDA achieved 88.9% of target.
• The company entered into a merger agreement with certain affiliates of Patient Square Capital, LP on September 21, 2025, which, if consummated, would result in a change in control.
• Stock ownership guidelines for certain NEOs and non-employee directors were increased in April 2025.

Sentiment

Score: 4

Explanation: The filing is primarily administrative, providing required Part III information. While the FY2025 AIP Corporate Score was above target, driven by strong Free Cash Flow, the significant failure to meet the threshold for the FY2023 PSAs and the 'disappointing' say-on-pay vote indicate underlying performance and governance concerns. The pending merger agreement introduces a major external factor, but the filing itself presents mixed internal performance signals.

Positives

• Non-GAAP Free Cash Flow for fiscal year 2025 significantly exceeded its target, achieving 150.0% of the target of $146.7 million with an actual performance of $178.4 million.
• The overall Corporate Score for the Fiscal Year 2025 Annual Incentive Plan achieved 113.3% of target, leading to above-target payouts for NEOs.
• All named executive officers (Michael Alkire, Glenn Coleman, Andrew Brailo, David Klatsky) and all but one non-employee director had satisfied the recently increased stock ownership requirements as of June 30, 2025.
• The Board affirmatively determined that eight of its nine directors are independent in accordance with NASDAQ rules and corporate governance guidelines.
• The Audit and Compliance Committee oversees cybersecurity risk management, indicating a proactive approach to information security.

Negatives

• The Fiscal Year 2023 Performance Share Awards (PSAs) for the three-year cycle ending June 30, 2025, did not achieve the threshold performance level, resulting in a 0% payout for these awards. The aggregate Non-GAAP Adjusted EPS was $6.50 against a threshold of $8.73.
• Consolidated Net Revenue for the Fiscal Year 2025 Annual Incentive Plan was below target, achieving only 80.9% of the $959.3 million target with an actual performance of $919.4 million.
• Non-GAAP Consolidated Adjusted EBITDA for the Fiscal Year 2025 Annual Incentive Plan was below target, achieving 88.9% of the $266.9 million target with an actual performance of $260.4 million.
• The 2024 stockholder advisory vote on executive compensation (say-on-pay) received approximately 71.2% support, which management considered a "disappointing" outcome.
• Two Class III Directors, Peter S. Fine and Marvin O'Quinn, are not eligible for re-nomination at the 2025 annual meeting due to reaching the age of 72, indicating upcoming changes to board composition.

Risks

• Disclosure of specific strategic objectives and performance targets could provide competitors with insights into confidential planning and strategies, potentially harming the company competitively.
• Executive compensation exceeding $1 million for covered employees is generally not tax-deductible under Code Section 162(m), potentially increasing the company's tax burden.
• Payments in connection with a change in control could trigger an excise tax under Internal Revenue Code Section 4999, although agreements include modified cutback provisions to mitigate this.
• Cybersecurity threats and data protection are identified as material risks requiring management and board oversight.
• The company's ability to attract and retain exceptional executive talent is crucial in a highly competitive market, and the loss of key executives could impact operational and strategic goals.
• The pending merger agreement with Patient Square Capital, LP, if not consummated, could lead to uncertainty and impact the company's operations and stock price.

Future Outlook

The company will continue its proactive stockholder outreach program to solicit input and understand perspectives on executive compensation. The Compensation Committee plans to annually review and reconfigure its peer group for compensation benchmarking and will establish performance measures for the remaining fiscal years (2026 and 2027) within the current three-year performance cycles for Performance Share Awards. Former CFO Craig McKasson is expected to continue serving as a consultant for two years following his retirement.

Management Comments

• "We were nevertheless disappointed by the outcome [of the 2024 stockholder say-on-pay vote]."
• "Stockholder feedback is very important to us, and we continue to take measured and appropriate steps to enhance transparency and disclosures regarding executive compensation."
• "We believe that Mr. Zito's effective oversight of the Performance Services business was not fully reflected in fiscal year 2025 performance because he joined the Company midway through the year."
• "We do not publicly disclose full information about specific goals or performance targets related to strategic objectives, as we believe that revealing these goals and targets would provide competitors and other third parties with insights into our confidential planning and strategies, thus potentially harming us competitively, as well as our stockholders."
• "We believe the performance awards are well designed with these two measures in combination because they: balance the focus of the awards on both our topand bottom-line growth; incorporate critical indicators of the long-term operational strength of our business...; and align the awards with long-term stockholder value creation."
• "We believe these provisions and agreements are necessary to attract and retain qualified people who will be free from undue concern about personal liability in connection with their service to us."

Industry Context

Operating within the healthcare industry, the company provides group purchasing organization (GPO) services, supply chain co-management, procure-to-pay solutions, and performance services including SaaS-based clinical analytics. Its executive compensation practices are benchmarked against a peer group of publicly traded companies in healthcare, technology, and general industries, reflecting the competitive landscape for executive talent in these sectors. The company's strategic objectives, such as digital supply chain agreements and cross-selling, align with broader industry trends towards efficiency and integrated solutions in healthcare.

Comparison to Industry Standards

• Executive compensation levels and structure are benchmarked annually against a peer group of 14 publicly traded companies, including AMN Healthcare Services, Inc., Dentsply Sirona Inc., and Owens & Minor, Inc., with Mercer serving as an independent compensation consultant.
• The company's stock ownership requirements for executives and directors, which were recently increased, are considered comparable to those of its peer group.
• The Directors Compensation Policy targets median competitive pay levels for non-employee directors, as evaluated no less frequently than every three years.
• The company does not offer executive perquisites common in many other companies, such as personal use of company aircraft, company vehicles, or health/country club memberships.
• The Dodd-Frank Compensation Recoupment Policy (clawback policy) complies with NASDAQ listing standards and the Dodd-Frank Act, aligning with current regulatory best practices.
• The CEO pay ratio for fiscal year 2025 was 54 to 1, which is lower than the ratios reported for fiscal years 2022 (71:1), 2023 (71:1), and 2024 (98:1).

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings adverse to the company or its subsidiaries were disclosed in the filing.

Related Party Transactions

• The Audit and Compliance Committee is responsible for reviewing and approving all related party transactions requiring disclosure under SEC Regulation S-K Item 404 (transactions exceeding $120,000 with directors, executive officers, and significant stockholders).
• The Member Agreement Review Committee reviews non-ordinary course transactions between the company or its subsidiaries and its member owners.
• No member of the Compensation Committee had any related person transaction involving the company during fiscal year 2025.
• No arrangements or understandings are known between any person serving as a director in fiscal year 2025 and any other person pursuant to which a director was or is to be elected or nominated, other than with directors or officers acting solely in their capacities.
• No directors, executive officers, or their associates are party to any material proceedings adverse to the company or have a material interest adverse to the company or its subsidiaries.

Stakeholder Impact

• Shareholders: Directly impacted by executive compensation decisions, the outcome of the say-on-pay vote, and the performance of equity awards. The pending merger agreement with Patient Square Capital, LP, if consummated, would result in a change in control, significantly impacting shareholder value and ownership structure.
• Employees: Executive compensation programs, including base salaries, annual incentives, and equity awards, directly affect NEOs and other employees. Participation in 401(k) and deferred compensation plans provides retirement benefits. Management changes and the potential merger could affect employee roles and organizational structure.
• Customers/Members: Strategic objectives tied to executive incentives, such as achieving targeted levels of digital supply chain agreements, contract penetration within existing GPO accounts, cross-selling Premier solutions, and expanding the customer footprint, aim to enhance value and service for customers and members.
• Suppliers: The company's supply chain services and strategic initiatives related to digital supply chain agreements could impact relationships and operations with suppliers.
• Regulatory Bodies: The filing demonstrates compliance with SEC regulations (e.g., Sarbanes-Oxley certifications, Dodd-Frank clawback policy) and NASDAQ listing standards, which is crucial for maintaining regulatory standing.

Next Steps

• The company does not intend to file a definitive proxy statement for an annual meeting of shareholders containing Part III information within 120 days after the end of its fiscal year ended June 30, 2025.
• Continue active engagement with stockholders to solicit input and better understand their perspectives regarding executive compensation programs.
• The Compensation Committee will establish performance measures for the fiscal years 2026 and 2027 within the current three-year performance cycles for Performance Share Awards.
• The merger agreement with certain affiliates of Patient Square Capital, LP, if consummated, would result in a change in control of the company.
• Former Chief Administrative and Financial Officer Craig McKasson will serve as a consultant to the company for two years following his retirement.

Key Dates

Recommendation

The filing is an administrative amendment to an annual report, not a primary financial results announcement. While the company demonstrated strong Free Cash Flow performance for FY2025, the failure to achieve threshold performance for the FY2023 PSAs and the below-target performance for Net Revenue and Adjusted EBITDA in FY2025's AIP indicate mixed operational results. The 'disappointing' say-on-pay vote suggests some investor dissatisfaction with compensation practices. The disclosure of a pending merger agreement with Patient Square Capital, LP is highly significant and price-sensitive, but the details of its impact are not fully elaborated in this specific filing beyond its existence. Given the administrative nature of this amendment and the mixed performance signals, a 'hold' recommendation is appropriate as investors await further details on the merger and future operational performance.

Keywords

Healthcare, SEC Filing, 10-K/A, Executive Compensation, Corporate Governance, Risk Management, Financial Reporting, Sarbanes-Oxley, Merger Agreement, Performance Shares, Restricted Stock Units, Non-GAAP Financial Measures, Audit Committee, Stock Ownership, Supply Chain Services, Performance Services, Patient Square Capital